Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCENIC: Inhaled RVT-1601 (cromolyn sodium) for persistent cough in idiopathic pulmonary fibrosis
2018-004447-23Phase 2Terminated
- Sponsor
- Respivant Sciences
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of RVT-1601 in idiopathic pulmonary fibrosis (IPF) and cough (4 arms), sponsored by Respivant Sciences. Started Mar 2019; status: terminated.
02
Drugs
RVT-1601
03
Conditions
idiopathic pulmonary fibrosis (IPF)cough
Beyond the preview
Go deeper on 2018-004447-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004447-23.